source
- Supreme Court rules generic maker Hikma does not infringe Amarin patents, easing skinny-label lawsuitsThe U.S. Supreme Court issued a unanimous decision that Hikma Pharmaceuticals did not violate patents owned by Amarin. The high court overturned a lower court ruling that had favored the brand name…
- Alnylam partners with Inceptive Nucleics on AI deal that could reach $2 billionAlnylam Pharmaceuticals announced a partnership with Inceptive Nucleics to apply artificial‑intelligence tools to its RNA‑based drug discovery program. The agreement provides an upfront $30 millio…